EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.
ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.
ESC HF 2021 In a nation-wide HF registry, screening for iron deficiency was performed in only 27% of patients. 19% Of patients with iron deficiency received treatment with ferric carboxymaltose.
Treatment with IV ferric carboxymaltose in patients with iron deficiency who had stabilized after acute HF led to greater improvements in health-related quality of life from week 4 to week 24 after discharge, compared to placebo.
The European Commission has extended the indication for empagliflozin and empagliflozin is now also approved for the treatment of adults with HFrEF.
ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.
ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.
ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.
Low gestational age at birth (<37 weeks) was associated with an increased risk for the development of HF into adulthood. The lower the gestational age of an infant at birth, the higher the risk for new-onset HF.
This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.
Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.
Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.